rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    XRTX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      12 Health Care Stocks Moving In Tuesday's After-Market Session
      Oct 20BenzingaXRTX
      Gout’s Standard Of Care Doesn’t Work For Everyone – XORTX Therapeutics Is Aiming To Change That With Its

      This post contains sponsored content and was created in collaboration with a third-party partner. Benzinga is a publisher and does not provide personalized investment advice or act as a broker or dealer. This content is

      Oct 14BenzingaXRTX
      12 Health Care Stocks Moving In Friday's After-Market Session - XORTX Therapeutics (NASDAQ:XRTX), 20/20 B

      Gainers XORTX Therapeutics (NASDAQ:XRTX) shares moved upwards by 7.8% to $1.52 during Friday's after-market session. The market value of their outstanding shares is at $3.3 million. 20/20 Biolabs (NASDAQ:AIDX)

      Oct 9BenzingaSXTCXRTX
      XORTX Moves to File Health Canada Trial Application for XRx-026 Gout Program

      Tipranks Press Release.

      Oct 9The Globe and MailXRTX
      XORTX Therapeutics Shares Climb Over 22% After Hours - XORTX Therapeutics (NASDAQ:XRTX)

      XORTX Therapeutics shares climb 22.16% after hours as company advances plans for a Canadian gout drug trial.

      Oct 9BenzingaXRTX
      Xortx Therapeutics Shares Rise After Company Reports Potential Partner Interest for Gout Program
      Oct 8Yahoo FinanceXRTX
      XORTX Outlines Anticipated Health Canada Clinical Trial Application for XRx-026 for Gout
      Oct 8Yahoo FinanceXRTX
      12 Health Care Stocks Moving In Thursday's After-Market Session - SCWorx (NASDAQ:WORX), XORTX Therapeutic
      Oct 8BenzingaXRTX
      Gout Treatments Need A Better Option: XORTX Therapeutics Is Betting XORLO Is It, Targets New Drug Application With FDA Next Year

      DETROIT, MICHIGAN- October 7, 2026- Blame it on an aging population, obesity, lifestyle choices or a combination of all the above, but either way, the number of cases of gout globally is projected to rise significantly in the next twenty-five years. As it stands, over 9 million people in the U.S. have been diagnosed with gout. That's where XORTX Therapeutics Inc., a...

      Oct 7NasdaqXRTX
      Gout Treatments Need A Better Option – XORTX Therapeutics Is Betting XORLO Is It, Targets New Drug Applic

      This post contains sponsored content and was created in collaboration with a third-party partner. Benzinga is a publisher and does not provide personalized investment advice or act as a broker or dealer. This content is

      Oct 6BenzingaXRTX
      XORTX Announces Planned FDA IND Submission for XRx-026 Gout Program Using XORLO™, Targeting USD$700M+ U.S. Gout Market Opportunity

      Investigational New Drug application planned for submission to the U.S. FDA in the fourth quarter of 2026, advancing the Company’s regulatory path toward NDA filing for gout program XRx-026CALGARY, Alberta, Sept. 18, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. (“XORTX” or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, outlines its anticipated Investigational New Drug applica

      Sep 18Yahoo FinanceXRTX
      XORTX Starts Clinical and Commercial Manufacturing of XORLO for Gout Program

      Detailed price information for Xortx Therapeutics Inc (XRTX-Q) from The Globe and Mail including charting and trades.

      Sep 11The Globe and MailXRTX
      XORTX Therapeutics Shares Rise 16.11% After Hours - XORTX Therapeutics (NASDAQ:XRTX)
      Sep 11BenzingaXRTX
      XORTX Announces Initiation of Clinical and Commercial Manufacturing of XORLO™

      ● Contract manufacturing of GMP drug substance and commercial-scale tablets to support the XRX-OXY-102 clinical study and future US FDA marketing approval ● CALGARY, Alberta, Sept. 10, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces the launch of production of drug material and tablet manufacturing to support t

      Sep 10Yahoo FinanceXRTX
      XORTX Re-Engages IR Firm After TSXV Delisting to Bolster Nasdaq-Focused Profile

      Detailed price information for Xortx Therapeutics Inc (XRTX-Q) from The Globe and Mail including charting and trades.

      Sep 9The Globe and MailXRTX
      XORTX Re-Engages Investor Relations Program

      CALGARY, Alberta, Sept. 08, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ('XORTX ' or the “Company ”) announces that, following completion o...

      Sep 8Business InsiderXRTX
      XORTX Announces Termination and Postponement of Investor Relations Program

      CALGARY, Alberta, Aug. 28, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that, effective August 7, 2026, it terminated its previously announced investor relations and marketing agreement dated May 13, 2026 with IR Agency LLC (the “IR Agreement”). The IR Agreement had a 90-day term

      Aug 28Yahoo FinanceXRTX

      This is the newest page. Registered accounts read further back.